| 18.96 0.45 (2.43%) | 08-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
MorphoSys AG is a commercial-stage biopharmaceutical company dedicated to the discovery, advancement, and marketing of innovative therapeutic antibodies aimed at treating cancer and autoimmune disorders. While its commercial operations are primarily situated in the United States, its development and partnership activities span globally. A key commercial offering is Tafasitamab, an antibody prescribed for various B-cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company's robust developmental pipeline includes Pelabresib, a small molecule undergoing Phase II trials for myelofibrosis; Felzartamab, an antibody targeting CD38, currently in Phase I/II studies for the autoimmune condition anti-PLA2R-positive membranous nephropathy; and CPI-0209, a small molecule in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. MorphoSys also participates in several partnered programs, such as Gantenerumab, an antibody for Alzheimer's disease; Otilimab for rheumatoid arthritis; Tremfya, used in psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody focused on immuno-oncology and autoimmune diseases. Strategic alliances are crucial to its business model, encompassing a regional licensing agreement with I-Mab Biopharma for felzartamab in China, Taiwan, Hong Kong, and Macau, alongside a strategic partnership with LEO Pharma. Furthermore, MorphoSys holds a joint collaboration and license agreement with Incyte Corporation for the development and commercialization of tafasitamab. A clinical collaboration also exists with Incyte Corporation and Xencor, Inc., exploring a combination therapy of tafasitamab, plamotamab, and lenalidomide for patients with relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. Established in 1992, MorphoSys AG's corporate headquarters are located in Planegg, Germany.
Wed, 17 Jul 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders - GlobeNewswire
Thu, 20 Jun 2024
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders - Business Wire
Thu, 14 Mar 2024
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - Business Wire
Wed, 15 Jun 2022
I-Mab Partner MorphoSys Announces New License Agreements for Felzartamab and TJ210 - PR Newswire
Wed, 02 Jun 2021
MorphoSys (MOR) to Acquire Constellations Pharmaceuticals (CNST), Stock Jumps - AskTraders
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|